In a proof‐of‐concept study, we demonstrated that the administration of these two short peptides independently triggered microencapsulated engineered monoclonal human cells stably expressing the best‐performing ComREXTRA‐based system to produce and release sufficient insulin to restore normoglycemia in a mouse model of type‐1 diabetes (T1D). Here, INS is linked to type 1 diabetes mellitus.